gastroenterologist-2016_posters-accepted-abstracts

4 / 24

Notes:
Page 78
Gastro 2016
August 11-12, 2016
Volume 6, Issue 4(Suppl) J Gastrointest Dig Syst 2016
ISSN:2161-069X JGDS, an open access journal
conferenceseries .com
August 11-12, 2016 Birmingham, UK
6th Global Gastroenterologists Meeting
Hector Martínez-Gomez et al., J Gastrointest Dig Syst 2016, 6:4(Suppl)
Pancreatic cancer: Experience at Hospital de Oncologia National Medical Center, Mexico
Hector Martínez-Gomez and Daniel López-Hernández
Instituto Mexicano del Seguro Social, Mexico
Pancreatic cancer is the fifth cause of death in developing countries, there are 232,000 new cases every year diagnosed
around the world with an incidence of 10.9 by 100,000 people, 37,700 are diagnosed as new cases and 34,000 deaths,
only 20% are found at diagnosis and only 5% are resectable. In Mexico, 13,080 new cases are reported every year and it do
represent fifth place among males and seventh place for women. 353 pancreatic cancer new patients are admitted every year at
Hospital de Oncología in Mexico. Between 1995 and 2005, there has been reported 75% of pancreatic fistulaes with mortality
of 19% and 75% morbidity. Soon it was decided that a three surgeons’ group should get additional training for performing the
procedure. Between January 2010 and July 2012, 78 patients were admitted for pancreatoduodenectomy, 28 (35%) of them
were not resectable during laparotomy, 4 patients (5%) experienced disease progression. There were 3 (4%) deaths during the
immediate postoperative period and the causes were lung embolism, pancreatic-yeyuno anastomosis dehiscencia with sepsis,
and mesenteric thrombosis. There were 10 patients with complications (12%) including pancreatico-yeyuno anastomosis
dehiscencia in 5 patients, hepato-yeyuno anastomosis dehiscencia in 4 patients and bleeding in 3 patients. The bleeding was
between 550 ml and 1000 ml and the average operating time was 6 hours. Hospital staying was between 7 and 10 days and none
patient required intensive care unit admission. Survival was 35% at 3 years and recurrence 25%.
Biography
Héctor Martínez-Gómez is serving as an esteemed doctor in Hospital de Oncología National Medical, Center Mexico. He is the recipient of numerous awards for
his expert research works in related fields. His research interests reflect in his wide range of publications in various national and international journals.